Active, not recruitingPHASE1, PHASE2NCT05275777

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National University Hospital, Singapore
Principal Investigator
Soo Chin Lee
National University Hospital, Singapore
Intervention
ADG106(drug)
Enrollment
66 target
Eligibility
18-99 years · All sexes
Timeline
20222030

Study locations (1)

Collaborators

Adagene Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05275777 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials